- Home
- HLNE vs PTGX Comparison
HLNE vs PTGX Comparison
Compare HLNE & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HLNE | PTGX |
|---|---|---|
| Founded | 1991 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.4B |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | HLNE | PTGX |
|---|---|---|
| Price | $129.69 | $95.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $160.56 | $88.33 |
| AVG Volume (30 Days) | 505.9K | ★ 953.6K |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ 19.80 | N/A |
| EPS | ★ 5.55 | 0.72 |
| Revenue | ★ $733,070,000.00 | $209,217,000.00 |
| Revenue This Year | $8.42 | N/A |
| Revenue Next Year | $19.65 | $296.47 |
| P/E Ratio | ★ $23.48 | $132.39 |
| Revenue Growth | ★ 13.01 | N/A |
| 52 Week Low | $111.98 | $33.70 |
| 52 Week High | $179.19 | $95.39 |
Technical Indicators
Market Signals| Indicator | HLNE | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 71.62 |
| Support Level | $121.55 | $88.30 |
| Resistance Level | $135.56 | $92.80 |
| Average True Range (ATR) | 4.19 | 2.80 |
| MACD | 0.89 | 0.30 |
| Stochastic Oscillator | 60.86 | 87.44 |
Price Performance
Historical ComparisonAbout HLNE Hamilton Lane Incorporated
Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.